- About Breast Cancer
- Community Impact
- Get Involved
2020 Komen New Jersey Breast Cancer Conference
Thank you for joining us at the 2020 Breast Cancer Conference!View Photos
This year’s conference focused on bringing together oncology experts to share their knowledge and approaches to advancing precision medicine in clinical practice – as it is rapidly becoming the most studied form of cancer therapy and the standard of care for patients with advanced breast cancer. The goal is to educate the care team on emerging developments and advancements of diagnostic, prognostic and therapeutic approaches that are advancing precision medicine in breast cancer care.
The conference agenda featured a keynote presentation, lunch presentation, six breakout sessions and networking opportunities.
Jointly Provided by Susan G. Komen Central and South Jersey and American Academy of CME, Inc.
8 am • Registration & Breakfast
8:30 am • Keynote Presentation with Komen Scholar Dr. Antonio Wolff
The Role of Prognostic and Predictive Biomarkers in
Improving the Survivorship Experience of Breast Cancer Patients
9:45 am – 10:45 am • Breakouts
10:45 am – 11 am • Snack Break
11 am – 12 pm • Breakouts
The CME/CE Portion of the Conference Is Supported Through Education Grants from:
Daiichi Sankyo ● Genentech ● Novartis ● Pfizer ● Seattle Genetics
Additional Conference Support Provided By
12 pm • Lunchtime Presentation
(CME/CE credit not available)
A New View of an Old Enemy – How Breast Cancer Treatment Looks in 2020
Dr. Patrick Borgen, Chair, Department of Surgery, Director, Breast Cancer, Maimonides Medical
Meet Our Keynote Speaker
Komen Scholar Since 2010
Johns Hopkins University School of Medicine
Antonio C. Wolff, M.D., is Professor of Oncology at Johns Hopkins University and a member of the Johns Hopkins Kimmel Cancer Center. A clinician and researcher, Dr. Wolff’s research interests include new treatment strategies, the development and implementation of prognostic and predictive biomarkers (tissue, blood, and imaging) in clinical practice, and how to improve the survivorship experience of breast cancer patients and their caregivers.
He promotes the implementation of research findings in clinical practice, survivorship, and quality of care for breast cancer patients. Dr. Wolff is the Chief Operating Officer of the Translational Breast Cancer Research Consortium (TBCRC)—a research group funded by Komen and that convenes a multidisciplinary group of researchers who plan and conduct studies to better understand breast cancer biology and test new therapies. He is also an Associate Editor of the Journal of Clinical Oncology and Chair of the NCI ECOG-ACRIN Breast Cancer Committee. Dr. Wolff’s Komen funding supports the development of a tissue and bodily fluid repository that has patient samples linked to clinical data and surveys that can be used to answer critical research questions.
Meet Our Presenters
Accreditation and CME/CE Credit Information
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 3.0 ANCC contact hours (pharmacotherapeutic contact hours pending).
Per the AAPA, PAs attending an educational activity that has been designated for AMA PRA Category 1 Credit™ may claim up to the maximum number of credits designated.
Other Team Members
Other members of the breast cancer care team will receive a certificate of participation.